Avantor and Catalent have entered into a multi-year supply and services agreement.
Avantor announced on Jan. 9, 2023 that it has entered into a multi-year supply and services agreement with Catalent. Under the agreement, Avantor will become the primary supplier of a broad range of laboratory supplies, clinical and productions materials, and services to Catalent. The agreement will expand the companies’ existing relationship and offer more choices to customers.
"We have seen firsthand that Avantor is a terrific partner that brings diverse capabilities and expertise across modalities and geographies, which is essential to meeting global health needs," said Alessandro Maselli, president and CEO, Catalent. "We look forward to deepening our work with the Avantor team to bring current and novel treatments to patients around the world."
"Catalent has built tremendous global capabilities and a reputation as a trusted collaborator to pharma, biotech, and consumer health partners throughout the development and production lifecycle," said Michael Stubblefield, president and CEO, Avantor. "We are pleased to expand our support for Catalent and enable efficiencies to accelerate science for their customers around the globe."
Source: Avantor
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.